It's more likely that we will have breakthroughs that work alongside things we don't know how to utilize yet.

The future holds the potential to eradicate diseases, with nonprofits working to identify all human druggable targets to aid the drug industry.

Using existing technology and modifying it can lead to innovative solutions, as seen with companies that repurpose off-the-shelf products for new applications.

Investing in unconventional scientific projects can lead to transformative discoveries, as seen with the potential of lizard venom-derived drugs for treating diseases.

There's a significant opportunity in generating in vivo data, which is currently limited, to better understand drug interactions in real biological systems, and we're seeing breakthroughs in data-generating technology in biology and chemistry that will significantly impact how we model these fields.

To achieve transformative drug design, we need several more breakthroughs similar to AlphaFold, focusing on different core concepts of biology and chemistry.

Drug companies are incentivized to find new uses for existing drugs rather than discover new ones, which is a serious problem in the pharmaceutical industry.

Drug design is complex, with numerous bottlenecks before reaching clinical trials, and we need to innovate in this space to improve the process.

Partnerships with Eli Lilly and Novartis have allowed us to tackle challenging problems in drug design, leading to the discovery of new chemical matter.